Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 ...Middle East

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing...

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 )

Also on site :

• Matthew Goode Explains Absence From ‘Downton Abbey 3’: “Maybe It’s A Good Thing”
• ‘America is not for sale:’ Protesters mob Trump golf course guests ahead of exclusive crypto dinner
• Spirit Halloween Issues Notice About 'Disruptions' Impacting Upcoming Season Opening